Relypsa Stock Rating Reaffirmed by Stifel Nicolaus (RLYP)
Relypsa (NASDAQ:RLYP)‘s stock had its “buy” rating restated by equities researchers at Stifel Nicolaus in a research report issued on Thursday, AnalystRatingsNetwork.com reports. They currently have a $45.00 price objective on the stock, down from their previous price objective of $49.00. Stifel Nicolaus’ target price would indicate a potential upside of 109.79% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Sterne Agee raised their price target on shares of Relypsa from $41.00 to $49.00 in a research note on Tuesday, March 18th. They now have a “buy” rating on the stock. Analysts at Wunderlich raised their price target on shares of Relypsa from $25.00 to $41.00 in a research note on Tuesday, February 11th. They now have a “buy” rating on the stock. Eight research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average price target of $44.33.
Shares of Relypsa (NASDAQ:RLYP) traded down 8.55% during mid-day trading on Thursday, hitting $19.615. 154,699 shares of the company’s stock traded hands. Relypsa has a one year low of $11.55 and a one year high of $52.74. The stock has a 50-day moving average of $27.49 and a 200-day moving average of $29.41. The company’s market cap is $582.8 million.
Relypsa (NASDAQ:RLYP) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.54) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.56) by $0.02. Analysts expect that Relypsa will post $-2.69 EPS for the current fiscal year.
Relypsa, Inc is a pharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.